Eurofins Scientific SE · EURONEXT:ERF

Eurofins Scientific — Debt Investor Presentation (January 2019)

53 slides from Eurofins Scientific's debt investor presentation, January 2019

  1. Slide 1: Eurofins Corporate Credit Presentation January 2019

    Eurofins A global leader in bioanalytical testing in the food, environment, pharmaceutical, agrosciences and clinical sectors Consistently delivering strong, sustainable, profitable growth Doubled revenues more than 3 times (every 3 years on average) between 2005 and 2017 Sales & EBITDA multiplied b

  2. Slide 2: Disclaimer

    Disclaimer The statements made during this presentation or as response to questions during the Question & Answers period that are not historical facts are forward looking statements. Furthermore, estimates and judgements may be made based on market and competitive information available at a certain

  3. Slide 3: Contents

    Contents  Eurofins at a glance  Market & Strategic Positioning  Finance & Outlook  Appendix 3

  4. Slide 4: Eurofins' Mission and key figures

    Eurofins’ Mission is to contribute to global Health, Safety & Environment with the best in bioanalysis  Founded in 1987  IPO in 1997 in Paris at EUR 1.83 per share (vs EUR 326.00 at 31/12/2018) Eurofins provides testing  Over 45,000 employees accross more than 650 laboratories in 45 services in f

  5. Slide 5: Leading global and local market positions (1/2)

    Leading global and local market positions in attractive high-growth markets* (1/2)… Testing for Food & Feed Environment Clinical Pharma/Biotech/Agrosciences Testing Testing Diagnostics N°1 to N°3* N°1* N°1* Start-Up Eurofins position worldwide worldwide worldwide Start 2014 Start 2000-2005 Start 198

  6. Slide 6: Leading global and local market positions (2/2)

    Leading global and local market positions in attractive high-growth markets* (2/2) Testing for Food & Feed Environment Clinical Pharma/Biotech/Agrosciences Testing Testing Diagnostics N°1 to N°3* N°1* N°1* Start-Up Eurofins position worldwide worldwide worldwide Start 2014 Start 2000-2005 Start 1987

  7. Slide 7: International network of standardised laboratories

    An international network of world class, standardised laboratories is attractive for our customers H1 2018 revenue split : N. America 31.7% France 21.2% Germany 11.5% Benelux 6.9% UK & Ireland 6.4% Entry into high-growth Nordic Region 6.3% markets with start ups Others 16.0% & acquisitions 80% of th

  8. Slide 8: Upwards revision of objectives to double revenues

    Upwards revision of objectives to once again double revenues in only 3 years (between 2015 and 2018) instead of 5, and reach €5bn in 2020 vs €4bn originally planned in 2015 for 2020 Illustration of Eurofins’ 2018-2020 growth objectives assuming constant/linear acquisition volume and growth rate each

  9. Slide 9: Contents

    Contents  Eurofins at a glance  Market & Strategic Positioning  Finance & Outlook  Appendix 9

  10. Slide 10: Our company DNA

    What we are passionate about: Our company DNA Testing for Life Entrepreneurship Everything we do has a positive We are a network of independent, impact on LIFE, HEALTH and the ENVIRONMENT. intrapreneur-led companies and a school for those who aspire to become Results entrepreneurs. Eurofins launches

  11. Slide 11: Drivers for high long-term above GDP market growth

    Drivers for high long-term above GDP market growth Secular Underlying Fundamentals General Market Drivers Laboratory Market Drivers Consumer Demand for safe Increasing wealth expectations for pharmaceuticals, quality food and quality of Life protection and clean environment Consolidation of the frag

  12. Slide 12: High barriers to entry, reinforcing leadership

    Building leadership positions in an industry with significant network effects and competitive advantage for the market leader High level of investment and innovation required to build and efficiently run a network of modern laboratories (buildings, equipment, IT High barriers infrastructure and solu

  13. Slide 13: Eurofins is the leader in most of its markets

    Eurofins is the leader in most of its markets and continues to build global & local leadership positions* in markets where scale matters New Markets 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 Denmark: Food and Environment Testing Sweden, Norway: Food an

  14. Slide 14: Industry with attractive and resilient organic growth

    Building leadership positions in an industry with attractive and resilient organic growth characteristics  Market Structural growth: ~1.5-2x Gross Domestic Product (GDP) growth, globalization, urbanization, increasing need and demand for a healthier life and safer environment. Testing is the most e

  15. Slide 15: Sustainable Development Goals efforts

    Eurofins’ Sustainable Development Goals (SGD) efforts towards a safer and healthier World in line with its Mission of “Testing for Life” Eurofins’ Mission:  To contribute to a safer and healthier world by providing our customers with innovative and high quality laboratory and advisory services whil

  16. Slide 16: ESG actions in detail (1/2) - Governance

    Eurofins’ ESG actions in detail (1/2) - Governance  Eurofins Board of Directors comprises 50% of independent, non-executive Directors  Eurofins Board of Directors comprises 50% of women both executive and non-executive  Eurofins currently has three independent governing Committees:  Audit Commit

  17. Slide 17: ESG actions in detail (2/2) - Governance

    Eurofins’ ESG actions in detail (2/2) - Governance  Key governance codes:  Eurofins Group Code of Ethics  Ten Principles of the United Nations Global Compact  Ten Principles of Corporate Governance of the Luxemburg Stock Exchange  Compliance with a large number of industry norms, compliance wit

  18. Slide 18: ESG Case Study: Eurofins Lancaster Laboratories

    ESG Case Study: Eurofins Lancaster Laboratories Eurofins Lancaster Laboratories (ELL), the largest independent single-site laboratory in the World with more than 1,700 employees, publishes a Sustainability Report on an annual basis. Here are some highlights from their 2017 Sustainability Report: Env

  19. Slide 19: Contents

    Contents  Eurofins at a glance  Market & Strategic Positioning  Finance & Outlook  Appendix 19

  20. Slide 20: Strong revenue growth in Q3 2018, raised objectives

    Eurofins posted strong revenue growth in Q3 2018 and raised its objectives for 2019-2020 Revenues objective for 2020 now set at EUR 5bn Q3/NM 2018: Eurofins continues to make significant progress towards its five year 2015-2020 plan to build a unique, highly efficient hard to replicate state-of-the-

  21. Slide 21: Strong revenue, profitability and cash flow growth in H1 2018

    Strong revenue, profitability and cash flow growth in H1 2018 Eurofins 3 year Report Card: H1 2015 – H1 2018 CAGR H1 2018: Strong growth & operating momentum  24.8% revenue growth to EUR 1,743m  Over 5% organic growth* in Q2 2018 and close to 5% for H1  EBITDA grew 31.4% to EUR 288m resulting in

  22. Slide 22: New number 1 leadership positions in U.S. and Europe

    In H1 2018, Eurofins reached new number 1 leadership positions in the U.S. and Europe thanks to organic growth, strategic acquisitions and start-up laboratories Eurofins has achieved new leadership positions in Food, Environment and Biopharma Product testing:  U.S. – market leader in Food testing –

  23. Slide 23: Acquisition of Covance Food Solutions

    Eurofins expands its footprint in North America, the UK and Asia with the acquisition of Covance Food Solutions  On August 1st 2018, Eurofins announced the successful closing of the transaction to acquire Covance Food Solutions (CFS) from LabCorp for USD 670m on a cash free debt free basis : CFS is

  24. Slide 24: Acquisition of TestAmerica

    In October 2018, Eurofins acquired TestAmerica, further expanding its environment testing footprint in North America  On October 31st 2018, Eurofins announced the closing of the acquisition of TestAmerica: the leading environment testing laboratory in the U.S., delivering innovative technical exper

  25. Slide 25: Debt instruments bear low fixed interest rates

    The majority of Eurofins’ debt instruments bear low fixed interest rates for long maturities Bond, Schuldschein & Hybrid Capital Maturity Profile Over the years, strict financial discipline has allowed Eurofins to significantly reduce its average cost of funding by refinancing older more expensive d

  26. Slide 26: Solid Balance Sheet

    Solid Balance Sheet Hybrid  EUR 300m hybrid issued in Jan 2013/Jul 2014, callable at par by Jun 2018 Dec 2017 Eurofins in Jan 2020. Bears a fixed coupon of 7.00% until first call, Euribor 3m + 818 bp thereafter if not called  EUR 300m hybrid issued in April 2015, callable at par by Eurofins  Net

  27. Slide 27: Strong financial discipline at all times

    Strong financial discipline at all times Average net debt/L12M EBITDA 21 acquisitions with total annualized revenue About 60 acquisitions with total annualized contribution of over EUR 570m. revenue contribution of ca. EUR 700m. Entry into 3 new countries Entry into 5 new countries 10 start-ups 30 s

  28. Slide 28: Outlook: becoming the world leader in bioanalytical testing

    Outlook: becoming the world leader in the bioanalytical testing market Sustainable Market Growth Drivers + Key Success Factors = Solid Outlook  Food safety & contamination  Unique technological portfolio of 2018 Objectives* issues over 150,000 methods  Over EUR 3.8bn of revenues  EUR 4.0bn of pr

  29. Slide 29: Conclusion: our sustainable competitive advantage

    Conclusion: our sustainable competitive advantage Best in class technology and quality give best brand High-growth, non-cyclical markets driven by secular protection mega-trends N° 1 or 2 worldwide in most business lines Advancing globalisation but with very few global Network in 45 countries testin

  30. Slide 30: Contents

    Contents  Eurofins at a glance  Market & Strategic Positioning  Finance & Outlook  Appendix 30

  31. Slide 31: The Pharma testing market is healthy and full of potential

    The Pharma testing market is both healthy and full of potential Need for big pharma Rapid technological change & companies to expand increasing complexity in testing new drugs pipelines require ongoing investment in technology & expertise  The increasing complexity of clinical trials leads to incre

  32. Slide 32: Eurofins Pharma Services in more detail

    Eurofins Pharma Services in more detail Spanning the entire drug development cycle Genomics Discovery Pre-clinical/ Clinical Development BioPharma Pharmacology Early (Central & Products Development Laboratory/ Manufacturing Testing Bioanalytical) Sequencing High-throughput- Pharmacology Biomarkers P

  33. Slide 33: Underlying trends are intact for continued growth

    Underlying trends are intact for continued growth Global Drug R&D Spending (US$ bn)  Pharmaceutical and biotechnology R&D spending is expected to rise to $161 bn in 2018  2017 was a record year in FDA novel drug approvals, the purest measure of biopharma pipeline productivity  Drug approvals fuel

  34. Slide 34: 9 of the top 10 pharma companies are clients

    9 of the top 10 largest global pharmaceutical companies are clients of Eurofins Eurofins pharma locations Global CRO Market Outlook Top 10 pharma companies Pfizer (US) Sanofi Aventis (FR) GlaxoSmithKline (UK) Novartis (CH) AstraZeneca (UK) Merck & Co (US) Johnson & Johnson (US) Roche (CH) Eli Lilly

  35. Slide 35: The Food testing market enjoys robust growth drivers

    The Food testing market enjoys robust growth drivers Food scares and Globalisation: Raw Consumers’ Outsourcing of crises, widely materials sourced increasing awareness industry’s covered in the from countries and demand for safe internal or state- media with different QC and high quality food owned

  36. Slide 36: Food & Feed testing offering is the most comprehensive

    Eurofins’ Food & Feed testing offering is the most comprehensive in the market Agricultural production, product Production Retail & Distribution development Microbiology Sensorial Dioxins Veterinary drug Vitamins Quality Control residues Authenticity Pesticides Organic residues POPs Labelling GMO My

  37. Slide 37: High profile food scares have expensive consequences

    High profile food scares have expensive consequences for producers… Brand / Year Contamination Impact Cost Source Country 2008 Sanlu/ Melamine in dairy 50,000 infants ill, 6 deaths, global recall of dairy and related products, criminal Unquantified BBC News Fronterra + products charges in China glob

  38. Slide 38: Meeting the demands of global players

    Eurofins is meeting the demands of global players for high quality testing  The largest global food & beverage producers and retailers are clients of Eurofins 2017 Sales in 2017 Sales in Food and Beverage Retailers EUR billion EUR billion Nestlé Switzerland 90.1 Wal-Mart Stores USA 485.9 PepsiCo US

  39. Slide 39: The Environmental testing market continues to grow

    The Environmental testing market continues to grow Rise in Progress in epidemiology contamination & & medicine has identified pollution issues more compounds as toxic  Increasing demand by citizens for a clean environment  EU expanding regulation (e.g. REACH)  Increasingly long list of products i

  40. Slide 40: Eurofins serves all main environmental testing markets

    Eurofins serves all the main environmental testing markets Eurofins is the No.1 environmental testing service provider in the world* Lancaster Environmental Consulting and Testing is the laboratory sampling companies of choice for Fortune 500 are natural partners companies in the USA WATER AIR SOIL

  41. Slide 41: Global trends in regulation support the business

    Global trends in regulation support the business  Strong regulated markets (EU, USA) are still amending and adding regulations  Eastern European rules catching up with EU  Fast development of regulation in Asia  Regulation used for support of trading blocks (e.g. EU, NAFTA, ASEAN) Major pieces o

  42. Slide 42: EU regulations a key driver for testing industry

    EU regulations a key driver for the testing industry – e.g. REACH directive Objectives Examples of affected products or industries  Listing and assessing the safety of 30,000 Metals, resins, acids, solvents, oils, fibres in textile, car chemical substances used by industries in components, toys, co

  43. Slide 43: Outsourcing adds to market growth

    Outsourcing adds to market growth Examples of laboratories outsourced to Eurofins Company Outsourced Activity Country Astellas Astellas Analytical Science Labs Japan Danish Hydrology Inst. Official water reference lab Scandinavia Suez/Sita Envirolab The Netherlands Danish farmers association Steins’

  44. Slide 44: Specialized Clinical Diagnostic Network Evolution

    Eurofins Specialized Clinical Diagnostic Network Evolution “Genomics is one of the key technologies enabling personalized medicine…” Establishing platform to deploy genomics expertise for development of innovative clinical diagnostic tests to serve global healthcare community One of the world’s lead

  45. Slide 45: Specialized Clinical Diagnostic Footprint

    Eurofins Specialized Clinical Diagnostic Footprint Establishing leadership in targeted higher-growth niche areas of the clinical testing market Clinical Genetics Japan Clinical Genetics India 45

  46. Slide 46: Portfolio of Clinical Diagnostics Laboratories in France

    Eurofins has built a valuable portfolio of Routine and Specialized Clinical Diagnostics Laboratories in France  Eurofins Clinical Diagnostics operations in France amount to ca. EUR 400m of revenues.  These EUR 400m revenues were acquired over the last 3 years for ca. 600-700m, representing an aver

  47. Slide 47: EAG entry into Materials and Engineering Sciences

    EAG provides Eurofins an entry into the dynamic and growing Materials and Engineering Sciences markets EAG believes that it holds the N°1 position in both Materials and Engineering Sciences markets, in the USA.  Materials and Engineering Sciences represent over 50% of EAG’s total revenue. The Mater

  48. Slide 48: EAG Platform Trajectory under Eurofins ownership

    EAG Platform Trajectory under Eurofins ownership EV* paid in 780 <900  Attractive EBITDA US$m multiples for bolt-on acquisitions led by 75 ~313 EAG’s leadership 225 6% 238 (single digits) ~216 Revenues  Solid organic growth in US$m mid-to-high single digit top-line and double- digit EBITDA  Syner

  49. Slide 49: Global leadership positions in niche markets

    Eurofins has established global leadership positions in 5 high potential niche markets Agroscience CRO Cosmetics Advanced Materials Genomic Services Discovery Pharmacology Services Testing Sciences N°2* Eurofins Worldwide N°1* N°1* N°1* N°1* position N°1* worldwide worldwide worldwide worldwide Euro

  50. Slide 50: Allocating cash flow towards building global platform

    Eurofins is allocating part of its cash flow towards building its leading global platform Cashflow expansion levers: cash investments impacting cashflows FCF invested €89m for the future €80m €75m €147m €81m €126m Reported FCF €57m to Equity €100m €19m €51m €46m €49m *Free Cash Flow to Equity - Oper

  51. Slide 51: Network Build-Out to Position for the Future

    Network Build-Out to Position for the Future Capex remains driven by network expansion investments Continuous investments in state-of-the-art IT solutions One IT (IT Solutions)  First Generation OneIT deployed in ca. 85% of Food and Environment laboratories  New Generation Genomics and Agroscience

  52. Slide 52: Post acquisition sales and profits often increase

    Post acquisition and integration into Eurofins, both sales and profits often increase significantly Illustration Growth drivers post acquisition: 1) Sales increase through cross selling of Actual example of an acquired lab: Eurofins lab specialities internationally 2) Cost reduction – focus on most

  53. Slide 53: Meaningful industry consolidation is underway

    Meaningful industry consolidation is underway Selection of recent significant transactions in the testing industry Date Company Acquirer Geography Sales (€m) EV (€m) EV/Sales (x) EV/EBITDA (x) 2018 September Genewiz Brooks Automation US 102 383 3.8x N/A July Halo Cambrex US 87 353 4.0x 15.7x March B

Eurofins Scientific — Debt Investor Presentation (January 2019) on 6ix